Abstract
Insulin-like growth factor-I modulates cell growth and survival, and is thought to be important in tumor development. A (CA)19 repeat polymorphism in the promoter region of IGF-I gene that may affect transcription activity has been implicated as a risk factor for cancer, but individual studies have been inconclusive or controversial. Therefore, we performed a meta-analysis of 17 studies with IGF-I (CA)19 repeat genotyping on 8,799 patients and 13,901 controls. There were seven studies with prostate cancer (2,307 cases; 2,622 controls), seven studies with breast cancer (3,533 cases; 7,771 controls), and three studies with colorectal cancer (2,959 cases; 3,508 controls). Overall, the random effects odds ratio (OR) for the (CA)19 versus non-(CA)19 allele was 1.03 [95% confidence interval (CI), 0.95–1.11], with some between-study heterogeneity (P < 0.0001). There was no suggestion of an overall effect either in recessive or dominant modeling of (CA)19 allele effects, and the comparison of (CA)19 homozygosity versus non-(CA)19 homozygosity also showed no differential susceptibility to cancer (OR, 0.99; 95% CI, 0.84–1.16). No effect of (CA)19 was seen in subjects of breast cancer (seven comparisons, OR = 1.03; 95% CI, 0.90–1.17, P = 0.005 for heterogeneity), prostate cancer (seven comparisons, OR = 1.08; 95% CI, 0.88–1.27; P = 0.0002 for heterogeneity) and colorectal cancer (three comparisons, OR = 0.96; 95% CI, 0.89–1.03, P = 0.36, no significant between-study heterogeneity). There was also no evidence that the (CA)19 allele associated with the risk of cancer in Caucasians and Asians. The meta-analysis shows that this (CA)19 repeat polymorphism is unlikely to be a major determinant of susceptibility to cancer on a wide population basis. However, a larger single study is required to further evaluate the association IGF-I (CA)19 polymorphisms and the cancer risk in a specific population.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Allen NE, Davey GK, Key TJ, Zhang S, Narod SA (2002) Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene. Cancer Epidemiol Biomarkers Prev 11:319–320
Cleveland RJ, Gammon MD, Edmiston SN, Teitelbaum SL, Britton JA, Terry MB, Eng SM, Neugut AI, Santella RM, Conway K (2006) IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis 27:758–765
Chen C, Freeman R, Voigt LF, Fitzpatrick A, Plymate SR, Weiss NS (2006) Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol Biomarkers Prev 15(12):2461–2466
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563–566
DeLellis K, Ingles S, Kolonel L, McKean-Cowdin R, Henderson B, Stanczyk F, Probst-Hensch NM (2003) IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 88:277–282
Daughaday WH, Rotwein P (1989) Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10:68–91
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
Frayling TM, Hattersley AT, McCarthy A, Holly J, Mitchell SM, Gloyn AL, Owen K, Davies D, Smith GD Ben-Shlomo Y (2002) A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance and fetal growth in UK populations. Diabetes 51:2313–2316
Friedrichsen DM, Hawley S, Shu J, Humphrey M, Sabacan L, Iwasaki L, Etzioni R, Ostrander EA, Stanford JL (2005) IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate 65:44–51
Figer A, Karasik YP, Baruch RG, Chetrit A, Papa MZ, Sade RB, Rizel S, Friedman E (2002) Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women. Isr Med Assoc J 4:759–762
González-Zuloeta Ladd AM, Liu F, Houben MP, Arias Vasquez A, Siemes C, Janssens AC, Coebergh JW, Hofman A, Janssen JA, Stricker BH, van Duijn CM. (2007) IGF-1 CA repeat variant and breast cancer risk in postmenopausal women. Eur J Cancer doi:10.1016/j.ejca.2007.04.026
Gebhardt F, Zanker KS, Brandt B (1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274:13176–13180
Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen P, Koistinen R, Seppälä M (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98:2612–2615
Hong Y, Pedersen NL , Brismar K, Hall K, de Faire U (1996) Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 81:1791–1797
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393–1396
Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG (2001) Replication validity of genetic association studies. Nat Genet 29:306–309
Ioannidis JP, Rosenberg PS, Goedert JJ, O’Brien TR (2002) Commentary: metaanalysis of individual participants’ data in genetic epidemiology. Am J Epidemiol 156:204–210
Jernstrom H, Chu W, Vesprini D, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, Narod SA (2001a) Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 72:144–154
Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M (2001b) Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10:377–384
Kato I, Eastham J, Li B, Smith M, Yu H (2003) Genotype–phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene. Eur J Epidemiol 18(3):203–209
Li L, Cicek MS, Casey G, Witte JS (2004) No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomarkers Prev 13:497–498
Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826
Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8–31, 1
LeRoith D, Raizada MK (ed) (1993) Proceedings of the 4th international symposium on insulin, IGFs, and their receptors, vol 343. Adv Exp Med Biol, 20–23 April 1993 Woods Hole, Massachusetts, pp 1–417
Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD (2005) Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 14(5):1204–1211
Ma J, Pollak MN, Giovannucci E et al (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620–625
Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN, Hankinson SE (2002) A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 100:332–336
Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprini D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollak M, Narod SA (2003) Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 12:1429–1437
Neuhausen SL, Slattery ML, Garner CP et al. (2005) Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: strong association of IRS1 G972R variant and cancer risk. Prostate 64:168–174
Pollak M (2000a) Insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res 10:S6–S7
Pollak M (2000b) Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224–1228
Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8):S4–S66
Parrizas M, LeRoith D (1997) Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 138:1355–1358
Petitti D (1994) Meta-analysis, decision analysis, and cost effectiveness analysis. Oxford University Press, New York
Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds) (2002) Cancer incidence in five continents, vol VIII. IARC Sci Publ 155:1–781
Rietveld I, Janssen JA, Hofman A, Pols HA, van Duijn CM, Lamberts SW (2003) A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. Eur J Endocrinol 148:171–175
Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP (1998) Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83:2286–2290
Rotwein P, Pollock KM, Didier DK, Krivi GG (1986) Organization and sequence of the human insulin-like growth factor I gene.Alternative RNA processing produces two insulin-like growth factor I precursor peptides. J Biol Chem 261:4828–4832
Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353
Schildkraut JM, Demark-Wahnefried W, Wenham RM, Grubber J, Jeffreys AS, Grambow SC, Marks JR, Moorman PG, Hoyo C, Ali S, Walther PJ (2005) IGF1 (CA)19 repeat and IGFBP3-202 A/C genotypes and the risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 14:403–408
Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Pollak MN, Franco EL; Biomarkers of cervical cancer risk study team (2007) Insulin-like growth factor-i and risk of high-grade cervical intraepithelial. Cancer Epidemiol Biomarkers Prev 16(4):716–722
Slattery ML, Murtaugh M, Caan B, Ma KN, Neuhausen S, Samowitz W (2005) Energy balance, insulin-related genes and risk of colon and rectal cancer. Int J Cancer: 115:148–154
Slattery ML, Samowitz W, Curtin K, Ma KN, Hoffman M, Caan B, Neuhausen S (2004) Associations among IRS1, IRS2, IGF1, and IGFBP-3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev 13(7):1206–1214
Tae HJ, Luo X, Kim KH (1994) Roles of CCAAT/enhancer-binding protein and its binding site on repression and derepression of acetyl-CoA carboxylase gene. J Biol Chem 269:10475–10484
Tsuchiya N, Wang L, Horikawa Y, Inouse T, Kakinuma H, Matsuura S, Sato K, Ogawa O, Kato T, Habuchi T (2005) CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol 26:225–231
Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM (2001) A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 50:637–642
Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19:251–253
Wen W, Gao YT, Shu XO, Yu H, Cai Q, Smith JR, Zheng W (2005) Insulinlike growth factor-I gene polymorphism and breast cancer risk in Chinese women. Int J Cancer 113:307–311
Wong H-L, DeLellis K, Nicole P-H, Woon-Puay K, David Van Den B, Hin-Peng L, Mimi CY, Sue AI (2005) A new single nucleotide polymorphism in the insulin-like growth factor i regulatory region associates with colorectal cancer risk in Singapore Chinese. Cancer Epidemiol Biomarkers Prev 14(1):144–150
Wagner K, Hemminki K, Israelsson E, Grzybowska E, Söderberg M, Pamula J, Pekala W, Zientek H, Mielzynska D, Siwinska E, Försti A (2005) Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer. Breast Cancer Res Treat 92:133–140
Weber JL, May PE (1989) Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 44:388–396
Yang RC, Roden RBS (2003) Genetic polymorphism and tumor immunotherapy. Curr Pharmacogenom 1:37–57
Yu H, Li BD, Smith M, Shi R, Berkel HJ, Kato I (2001) Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Res Treat 70:117–122
Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151–156
Acknowledgments
We thank Dr. Jianfeng Dai (Yale University) and Dr. Yan Huang (Fudan University) for their expert assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, X., Guan, J., Song, Y. et al. IGF-I (CA) repeat polymorphisms and risk of cancer: a meta-analysis. J Hum Genet 53, 227–238 (2008). https://doi.org/10.1007/s10038-007-0241-3
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-007-0241-3
Keywords
This article is cited by
-
Acromegaly presented with acne vulgaris: a retrospective study with 123 cases
Journal of Endocrinological Investigation (2023)
-
Genetic Variants in the Insulin-like Growth Factor Pathway and Colorectal Cancer Risk in the Netherlands Cohort Study
Scientific Reports (2015)
-
IGF1(CA)19 and IGFBP-3-202A/C Gene Polymorphism and Cancer Risk: A Meta-analysis
Cell Biochemistry and Biophysics (2014)
-
Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis
BMC Cancer (2013)
-
Polymorphic CA repeat length in insulin-like growth factor 1 and risk of breast cancer in Iranian women
Medical Oncology (2012)
